|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Solution structure of de novo macrocycle design12_ss== | | ==Solution structure of de novo macrocycle design12_ss== |
| - | <StructureSection load='6bet' size='340' side='right'caption='[[6bet]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='6bet' size='340' side='right'caption='[[6bet]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6bet]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BET OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BET FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6bet]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BET OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6BET FirstGlance]. <br> |
| - | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DLY:D-LYSINE'>DLY</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene>, <scene name='pdbligand=DVA:D-VALINE'>DVA</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DLY:D-LYSINE'>DLY</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene>, <scene name='pdbligand=DVA:D-VALINE'>DVA</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6bet FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bet OCA], [http://pdbe.org/6bet PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6bet RCSB], [http://www.ebi.ac.uk/pdbsum/6bet PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6bet ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6bet FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bet OCA], [https://pdbe.org/6bet PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6bet RCSB], [https://www.ebi.ac.uk/pdbsum/6bet PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6bet ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 20: |
Line 20: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Baker, D]] | + | [[Category: Baker D]] |
| - | [[Category: Hosseinzadeh, P]] | + | [[Category: Hosseinzadeh P]] |
| - | [[Category: Pardo-Avila, F]] | + | [[Category: Pardo-Avila F]] |
| - | [[Category: Shortridge, M D]] | + | [[Category: Shortridge MD]] |
| - | [[Category: Varani, G]] | + | [[Category: Varani G]] |
| - | [[Category: De novo]]
| + | |
| - | [[Category: De novo protein]]
| + | |
| - | [[Category: Macrocycle]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics identified to date, but there is currently no way to systematically search the structural space spanned by such compounds. Natural proteins do not provide a useful guide: Peptide macrocycles lack regular secondary structures and hydrophobic cores, and can contain local structures not accessible with l-amino acids. Here, we enumerate the stable structures that can be adopted by macrocyclic peptides composed of l- and d-amino acids by near-exhaustive backbone sampling followed by sequence design and energy landscape calculations. We identify more than 200 designs predicted to fold into single stable structures, many times more than the number of currently available unbound peptide macrocycle structures. Nuclear magnetic resonance structures of 9 of 12 designed 7- to 10-residue macrocycles, and three 11- to 14-residue bicyclic designs, are close to the computational models. Our results provide a nearly complete coverage of the rich space of structures possible for short peptide macrocycles and vastly increase the available starting scaffolds for both rational drug design and library selection methods.
Comprehensive computational design of ordered peptide macrocycles.,Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D. Comprehensive computational design of ordered peptide macrocycles. Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347 doi:http://dx.doi.org/10.1126/science.aap7577
|